<DOC>
	<DOCNO>NCT00236119</DOCNO>
	<brief_summary>A 12-Week , Exploratory , Open-Label , Nonrandomized , Dose-Escalation Study Efficacy , Safety Tolerability Oral CEP-701 Patients Severe , Recalcitrant , Plaque Type Psoriasis .</brief_summary>
	<brief_title>Study Efficacy , Safety Tolerability Oral CEP-701 Patients With Severe Psoriasis</brief_title>
	<detailed_description>A 12-Week , Exploratory , Open-Label , Nonrandomized , Dose-Escalation Study Efficacy , Safety Tolerability Oral CEP-701 Patients Severe , Recalcitrant , Plaque Type Psoriasis .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Patients include study follow criterion meet : patient least 21 year old . The patient sever , recalcitrant , plaquetype psoriasis fail least 1 systemic therapy ( purpose study psoralen ultraviolet light A consider systemic therapy ) . The patient psoriatic involvement least 10 % BSA . The patient PSGA score 4 great . The patient , woman , surgically sterile 2 year postmenopausal , childbearing potential currently use medically accept method contraception , agree continue use method duration study ( 30 day participation study ) . Acceptable method contraception include : abstinence , steroidal contraceptive ( oral , transdermal , implanted , inject ) conjunction barrier method , intrauterine device ( IUD ) . The patient , main , surgically sterile , capable produce offspring , currently use approve method birth control , agree continue use method duration study ( 60 day take last dose CEP701 possible effect spermatogenesis ) . The patient must willing able comply study procedure restriction willing return clinic followup evaluation specify protocol . The patient receive treatment systemic psoriasis treatment ( specifically , retinoids , methotrexate , cyclosporine A , etanercept , efalizumab , biological agent immunomodulators ) within 4 week , UV base therapy within 2 week , alefacept within 6 week plan 1st day study treatment . The patient receive treatment potent CYP3A4 inhibitor include cyclosporine , clotrimazole , fluconazole , itraconazole , ketoconazole , voriconazole , erythromycin , clarithromycin , troleandomycin , human immunodeficiency virus ( HIV ) protease inhibitor , nefazodone within 1 week ( 7 day ) plan 1st day study treatment . The patient currently receive warfarin . The patient hypersensitivity CEP701 component CEP701 . The patient one follow serum chemistry value determine screen visit ( visit 1 ) : bilirubin level great 2 time upper limit normal ( ULN ) ALT AST level great 2 time ULN serum creatinine level 2mg/dL The patient require current treatment HIV protease inhibitor . The patient take medication clinical diagnosis gastrointestinal ulceration experience melena hematoemesis previous 3 week . The patient woman pregnant lactating . The patient receive treatment investigation drug within 4 week plan 1st day study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>